SEO URLwww.firestrike.ai/deals/avidity-biosciences-novartis-acquisition-2026-4

acquisitionAnnounced · Mar 17, 2026pharmaceuticalSource · CredibleArticle · Factual

Avidity Biosciences · Novartis

Novartis acquires Avidity Biosciences

David Najork · Founding Software Engineer

Announced Mar 17, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$12B

Target

Avidity Biosciences

NASDAQ: RNA · San Diego, California

Acquirer

Novartis

Full Acquisition

Status

Completed

Novartis agreed to acquire Avidity Biosciences. Reported deal value: $12B. Status: Completed. Sector: pharmaceutical. Target headquarters context: San Diego, California, United States.

This page summarizes publicly available information about the transaction as of 2026-03-17. Figures and status may change as filings and press coverage update.

× https://www. thehindubusinessline.com /companies/ novartis - sells - 11 - billion - bonds -to- fund - avidity - acquisition /article70752502.ece Copy Novartis AG raised $ 11 billion to help fund its purchase of Avidity Biosciences Inc., adding to a flurry of buyout-related bond sales

Deal timeline

Announced

Mar 17, 2026 · thehindubusinessline.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in pharmaceutical with a reported deal value of $12B. Figures and status may change as sources update.

Sources: thehindubusinessline.com · Primary article · FireStrike proprietary index